Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Additional file 3 of Single-cell profiling reveals a reduced epithelial defense system, decreased immune responses and the immune regulatory roles of different fibroblast subpopula... by Lin Lin (46073)

“…The red on the bubble plot shows the top increased metabolic pathways, and the blue shows the top decreased metabolic pathways. …”

Supporting information. by Yu Sang Choi (22656230)

Subjects:

Cinnamaldehyde repellency test within 6 hours in parthenogenesis <i>H. longicornis.</i> by Ceyan Kuang (8554557)

Subjects:

Correlation between Estimated Annual Percentage Change (EAPC) of <i><i>Klebsiella pneumoniae</i></i> associated lower respiratory infection (LRI) and death rates, and Socio-demogra... by Juanjuan Li (399633)

Subjects:

Age-specific numbers and rates of DALYs (A) and deaths (B) for <i><i>Klebsiella pneumoniae</i></i> associated LRI burden by sex, 2021. DALYs disability-adjusted life years. by Juanjuan Li (399633)

Subjects:

The trends in numbers of DALYs and deaths for <i><i>Klebsiella pneumoniae</i></i> associated LRI burden from 1990 to 2021. DALYs, disability-adjusted life years. by Juanjuan Li (399633)

Subjects:

Global and national estimates of deaths due to <i>Klebsiella pneumoniae</i>-associated lower respiratory infections in 1990 and 2021. by Juanjuan Li (399633)

Subjects:

The global disease burden of <i><i>Klebsiella pneumoniae</i></i> associated LRI for both sexes in 204 countries and territories. (a) The number of DALYs in 2021; (b) The EAPC of DA... by Juanjuan Li (399633)

Subjects:

Global and national estimates of disability-adjusted life years (DALYs) due to <i>Klebsiella pneumoniae</i>-associated lower respiratory infections in 1990 and 2021. by Juanjuan Li (399633)

Subjects:

The number and ASR of deaths for <i>Klebsiella pneumoniae</i>-related LRI burden in 1990 and 2021, and its trends from 1990 to 2021. by Juanjuan Li (399633)

Subjects:

The global disease burden of <i><i>Klebsiella pneumoniae</i></i> associated LRI for both sexes in 204 countries and territories. (a) The number of deaths in 2021; (b) The EAPC of d... by Juanjuan Li (399633)

Subjects:

The number and ASR of DALYs for <i>Klebsiella pneumoniae</i>-related LRI burden in 1990 and 2021, and its trends from 1990 to 2021. by Juanjuan Li (399633)

Subjects:

Table2_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.DOCX by Sofia Schaeffer (20379954)

“…Standardized sleep hygiene education did not produce significant changes in sleep parameters. Our findings indicate fragmented nocturnal sleep in patients with MASLD, characterized by increased wakefulness and reduced sleep efficiency, perceived subjectively as shortened sleep duration and delayed onset. …”